Noninvasive optical imaging of nitroreductase gene-directed enzyme prodrug therapy system in living animals

Gene Therapy

Volumn 19, Issue 3, 2012, Pages 295-302

  Bhaumik, S ^a   Sekar, T V ^b   Depuy, J ^a   Klimash, J ^a   Paulmurugan, R ^b  

^a GE GLOBAL RESEARCH   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

in vivo imaging; molecular imaging; nitroreductase; prodrug; reporter gene

Indexed keywords

CYTOCY5S; FLUORESCENT DYE; NITROREDUCTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; ENZYME KINETICS; ESCHERICHIA COLI; FLUORESCENCE IMAGING; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NONINVASIVE OPTICAL IMAGING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENE; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; AZIRIDINES; CELL LINE; ENZYME ACTIVATION; GENE EXPRESSION; GENE ORDER; GENETIC VECTORS; HUMANS; INTESTINES; KINETICS; METAGENOME; MICE; MICE, NUDE; MOLECULAR IMAGING; NEOPLASMS; NITROREDUCTASES; PRODRUGS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

ANIMALIA; BACTERIA (MICROORGANISMS);

EID: 84858008946     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.101     Document Type: Article

References (32)

1. Both GW. Recent progress in gene-directed enzyme prodrug therapy: an emerging cancer treatment. Curr Opin Mol Ther 2009; 11: 421-432.
2. Dachs GU, Hunt MA, Syddall S, Singleton DC, Patterson AV. Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules 2009; 14: 4517-4545.
3. Waerzeggers Y, Monfared P, Viel T, Winkeler A, Voges J, Jacobs AH. Methods to monitor gene therapy with molecular imaging. Methods (San Diego, CA) 2009; 48: 146-160.
4. Fass L. Imaging and cancer: a review. Mol Oncol 2008; 2: 115-152.
5. Morris JC, Ramsey WJ, Wildner O, Muslow HA, Aguilar-Cordova E, Blaese RM. A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidine kinase gene (AdV RSV-TK) in combination with escalating doses of ganciclovir in patients with cutaneous metastatic malignant melanoma. Hum Gene Ther 2000; 11: 487-503. (Pubitemid 30101958)
6. Crystal RG, Hirschowitz E, Lieberman M, Daly J, Kazam E, Henschke C et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum Gene Ther 1997; 8: 985-1001. (Pubitemid 27270161)
7. Cunningham C, Nemunaitis J. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001. Hum Gene Ther 2001; 12: 1594-1596.
8. Patel P, Young JG, Mautner V, Ashdown D, Bonney S, Pineda RG et al. A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984]. Mol Ther 2009; 17: 1292-1299.
9. Mailly L, Leboeuf C, Tiberghien P, Baumert T, Robinet E. Genetically engineered T-cells expressing a ganciclovir-sensitive HSV-tk suicide gene for the prevention of GvHD. Curr Opin Investig Drugs 2010; 11: 559-570.
10. Matthews K, Noker PE, Tian B, Grimes SD, Fulton R, Schweikart K et al. Identifying the safety profile of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adeno-virus, in anticipation of a phase I clinical trial in patients with recurrent ovarian cancer. Clin Cancer Res 2009; 15: 4131-4137.
11. Wang HE, Yu HM, Liu RS, Lin M, Gelovani JG, Hwang JJ et al. Molecular imaging with 123I-FIAU, 18F-FUdR, 18F-FET, and 18F-FDG for monitoring herpes simplex virus type 1 thymidine kinase and ganciclovir prodrug activation gene therapy of cancer. J Nucl Med 2006; 47: 1161-1171. (Pubitemid 47544911)
12. Liang Q, Gotts J, Satyamurthy N, Barrio J, Phelps ME, Gambhir SS et al. Noninvasive, repetitive, quantitative measurement of gene expression from a bicistronic message by positron emission tomography, following gene transfer with adenovirus. Mol Ther 2002; 6: 73-82. (Pubitemid 36124273)
13. Penuelas I, Haberkorn U, Yaghoubi S, Gambhir SS. Gene therapy imaging in patients for oncological applications. Eur J Nucl Med Mol Imaging 2005; 32(Suppl 2): S384-S403. (Pubitemid 41796402)
14. Serganova I, Ponomarev V, Blasberg R. Human reporter genes: potential use in clinical studies. Nucl Med Biol 2007; 34: 791-807. (Pubitemid 47503822)
15. Kang JH, Chung JK. Molecular-genetic imaging based on reporter gene expression. J Nucl Med 2008; 49(Suppl 2): 164S-179S.
16. Serganova I, Mayer-Kukuck P, Huang R, Blasberg R. Molecular imaging: reporter gene imaging. Handb Exp Pharmacol 2008; (185 pt 2): 167-223.
17. Bhaumik S, Lewis XZ, Gambhir SS. Optical imaging of Renilla luciferase, synthetic Renilla luciferase, and firefly luciferase reporter gene expression in living mice. J Biomed Opt 2004; 9: 578-586.
18. Hoffman RM. Imaging cancer dynamics in vivo at the tumor and cellular level with fluorescent proteins. Clin Exp Metastasis 2009; 26: 345-355.
19. Luker GD, Piwnica-Worms D. Molecular imaging in vivo with PET and SPECT. Acad Radiol 2001; 8: 4-14. (Pubitemid 32674635)
20. Wester HJ. Nuclear imaging probes: from bench to bedside. Clin Cancer Res 2007; 13: 3470-3481.
21. Both GW. Gene-directed enzyme prodrug therapy for cancer: a glimpse into the future? Discov Med 2009; 8: 97-103.
22. Haberkorn U. PET and SPECT. Handb Exp Pharmacol 2008; (185 Pt 2): 13-35.
23. Bhaumik S. Advances in imaging gene-directed enzyme prodrug therapy. Curr Pharm Biotechnol 2011; 12: 497-507.
24. Chung-Faye G, Palmer D, Anderson D, Clark J, Downes M, Baddeley J et al. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. Clin Cancer Res 2001; 7: 2662-2668. (Pubitemid 32911369)
25. Palmer DH, Mautner V, Mirza D, Oliff S, Gerritsen W, van der Sijp JR et al. Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J Clin Oncol 2004; 22: 1546-1552. (Pubitemid 41079791)
26. Searle PF, Chen MJ, Hu L, Race PR, Lovering AL, Grove JI et al. Nitroreductase: a prodrug-activating enzyme for cancer gene therapy. Clin Exp Pharmacol Physiol 2004; 31: 811-816. (Pubitemid 39556859)
27. Gambhir SS, Herschman HR, Cherry SR, Barrio JR, Satyamurthy N, Toyokuni T et al. Imaging transgene expression with radionuclide imaging technologies. Neoplasia 2000; 2: 118-138. (Pubitemid 30123184)
28. Helsby NA, Wheeler SJ, Pruijn FB, Palmer BD, Yang S, Denny WA et al. Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide- 5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation. Chem Res Toxicol 2003; 16: 469-478. (Pubitemid 36514504)
29. Jiang Y, Han J, Yu C, Vass SO, Searle PF, Browne P et al. Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation. J Med Chem 2006; 49: 4333-4343. (Pubitemid 44036677)
30. Kendall JM, Ismail R, Thomas N. Adenoviral sensors for high-content cellular analysis. Methods Enzymol 2006; 414: 247-266. (Pubitemid 44716226)
31. Bhaumik S, Gambhir SS. Optical imaging of Renilla luciferase reporter gene expression in living mice. Proc Natl Acad Sci USA 2002; 99: 377-382. (Pubitemid 34060369)
32. Smits AM, van den Hengel LG, van den Brink S, Metz CH, Doevendans PA, Goumans MJ. A new in vitro model for stem cell differentiation and interaction. Stem Cell Res 2009; 2: 108-112.